Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks. StoneCo, Centene, CVS Health and Pfizer have been highlighted ... and ...

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying ...

Pfizer’s recent earnings look solid at first glance, but there’s a quirky twist. A US$7 billion unusual expense dragged down ...

Pfizer is facing another setback with its weight ... COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday.

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...

Pfizer stock (NYSE: PFE) has recently announced its Q1 results, reporting revenues that fell short of expectations while earnings surpassed analyst predictions. The company disclosed revenue of $ ...